**Precautionary Check on Anticoagulant Drug: What Patients Should Do**
Health authorities in Cyprus are conducting a precautionary check on a specific batch of the anticoagulant medication Warfant 3mg following reports of packaging discrepancies. The issue has been identified in batch number 25002, where some packages may inadvertently contain 1mg tablets instead of the intended 3mg tablets.
The Health Insurance Organisation (HIO) announced the situation after being informed by the Pharmaceutical Services. In response, the HIO has issued a written notice to patients who have received the affected batch of Warfant, urging them to verify the contents of their medication.
Patients are advised to inspect the tablets within their packaging. The correct 3mg tablets are characterized by their blue color. If patients find tablets of a different color or have any uncertainty about their medication, they are instructed to take the packaging to the nearest pharmacy for further inspection.
In an official communication, the company responsible for Warfant stated that, after discussions with the Pharmaceutical Services and the marketing authorization holder, there will be no immediate recall of the affected batch from pharmacies. Instead, batch 25002 will remain available, provided that each package is thoroughly checked before dispensing.
Pharmacies have been directed to open each package in the presence of the patient prior to any sale or dispensing. They must confirm that the tablets are indeed blue. If any tablets of a different color are discovered, the pharmacy is required to withhold the product and notify the company immediately. Additionally, pharmacies are expected to contact any patients or other pharmacies that have previously received products from this batch.
To address any financial implications, the company has assured pharmacies that they will be compensated for any defective packages identified during these checks. Further instructions will be provided once a new, unaffected batch of Warfant becomes available.
Patients currently taking Warfant 3mg from batch 25002 are strongly encouraged to consult with a pharmacist for an immediate check of their medication. It is crucial that patients do not discontinue their treatment, alter their dosage, or take additional tablets without consulting a healthcare professional. Any adjustments to medication should only be made under the guidance of a doctor, pharmacist, or the relevant anticoagulation monitoring service.
Warfarin, commonly known by its brand name Warfant, is an anticoagulant that requires careful dosage management based on individual medical assessments and INR (International Normalized Ratio) test results. Taking a tablet of lower strength than prescribed could lead to inadequate anticoagulation, posing potential health risks.
As the situation develops, health authorities will continue to monitor the situation closely and provide updates to ensure patient safety and medication integrity. Patients are reminded to remain vigilant and proactive in managing their health, especially when it comes to medications that require precise dosing.
For further information, patients can reach out to their healthcare providers or local pharmacies.